Steady-state pharmacokinetics of Nevirapine in HIV-1 infected adults in India

Ramachandran, Geetha and Hemanth Kumar, A K and Rajasekaran, S and Padmapriyadarshini, C and Narendran, G and Anitha, S and Subramanyam, Sudha and Kumaraswami, V and Swaminathan, Soumya (2007) Steady-state pharmacokinetics of Nevirapine in HIV-1 infected adults in India. Journal of the International Association of Physicians in (Providers of) AIDS Care, 6 (4). pp. 251-254. ISSN Print: 2325-9574 Online: 2325-9582

[thumbnail of 200731.pdf] PDF
200731.pdf - Published Version
Restricted to Registered users only

Download (227kB) | Request a copy


Background and Objectives: A variety of demographic factors, sex, and degree of immunosuppression can influence antiretroviral drug concentratians. The authors studied the influence of immune status, sex, and body mass index (BMI) on the steady-state pharmacokinetics of nevirapine delivered as a fixed-dose combination in HIV-1-infected patients in India. Methods: Twenty-six HIV-l-infected adult patients undergoing treatment with nevirapine-based highly active antiretroviral therapy regimens participated in the study. Pharmacokinetic variables were compared between patients divided based an CD4 cell counts, sex, and BMI. Results: Patients with higher BMI had lower peak and trough concentration and exposure of nevirapine than those with lower BMI; none of the differences in the pharmacokinetic variables of nevirapine between the various patient groups was statistically significant. Conclusions: Patients' immune status, sex, or BMI had no impact on the pharmacokinetics of nevirapine. Plasma nevirapine concentrations were maintained within the therapeutic range of the drug in the majority of the patients.

Item Type: Article
Uncontrolled Keywords: pharmacokinectics; nevirapine; India: immune status sex; BMI
Subjects: Tuberculosis > Laboratory Research > Biochemical
Divisions: Basic Science Research > Biochemistry
Depositing User: Dr. Rathinasabapati R
Date Deposited: 09 Jan 2014 10:08
Last Modified: 30 Mar 2021 05:00

Actions (login required)

View Item View Item